Skip to main content
SpringerLink
Log in

Incompleteness of Lamotrigine Data

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2000; 22(4): 303–12

    Article  PubMed  CAS  Google Scholar 

  2. Besag FMC, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Paediatr 1995; 127: 991–7

    Article  CAS  Google Scholar 

  3. Mackay FJ, Wilton LV, Pearce GL, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38(8): 881–86

    Article  PubMed  CAS  Google Scholar 

  4. Wilton LV, Pearce GL, Mann RD. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf 1999; 8: S37–S45

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Incompleteness of Lamotrigine Data. Drug-Safety 24, 155 (2001). https://doi.org/10.2165/00002018-200124020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124020-00005

Keywords

Search

Navigation